The APCCC Diagnostics 2025 consensus conference evaluated 88 multiple-choice questions across six clinical topics related to prostate cancer diagnosis, staging, and restaging (including biochemical recurrence, metastatic disease monitoring, and radioligand therapy/imaging), with expert panel voting conducted via web-based survey.
Consensus (≥75% agreement) was reached on only 17 of 88 questions (19%), with strong consensus (≥90%) on just 6 (7%). Highest consensus rates were in staging (7/16, 44%) and lowest in monitoring metastatic disease (0/18, 0%).
Full text was not accessible — only the abstract was available, so specific voting results, panel composition, and detailed clinical recommendations cannot be assessed. The consensus format reflects expert opinion rather than primary evidence, and the pilot design limits generalizability.
Broad disagreement among experts highlights that most decisions around prostate cancer diagnosis and restaging lack high-level evidence — clinicians should approach these areas with awareness of uncertainty. Priority topics for future research include monitoring metastatic prostate cancer and radioligand therapy imaging guidance.
Explore related topics
